ITBO910024A0 - Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale - Google Patents

Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale

Info

Publication number
ITBO910024A0
ITBO910024A0 IT91BO24A ITBO910024A ITBO910024A0 IT BO910024 A0 ITBO910024 A0 IT BO910024A0 IT 91BO24 A IT91BO24 A IT 91BO24A IT BO910024 A ITBO910024 A IT BO910024A IT BO910024 A0 ITBO910024 A0 IT BO910024A0
Authority
IT
Italy
Prior art keywords
glycosaminoglicans
pharmaceutical formulations
formulations containing
containing orally
orally absorbable
Prior art date
Application number
IT91BO24A
Other languages
English (en)
Inventor
Manlio Cristofori
Egidio Marchi
Leone Gabriele Rotini
Original Assignee
Alfa Wassermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann filed Critical Alfa Wassermann
Publication of ITBO910024A0 publication Critical patent/ITBO910024A0/it
Priority to ITBO910024A priority Critical patent/IT1245761B/it
Priority to US07/821,455 priority patent/US5252339A/en
Priority to ES92100732T priority patent/ES2090368T3/es
Priority to DE69212608T priority patent/DE69212608T2/de
Priority to EP92100732A priority patent/EP0497162B1/en
Priority to CA002059865A priority patent/CA2059865C/en
Priority to JP4013943A priority patent/JPH0755907B2/ja
Priority to KR1019920001330A priority patent/KR100210359B1/ko
Publication of ITBO910024A1 publication Critical patent/ITBO910024A1/it
Application granted granted Critical
Publication of IT1245761B publication Critical patent/IT1245761B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITBO910024A 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. IT1245761B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ITBO910024A IT1245761B (it) 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
US07/821,455 US5252339A (en) 1991-01-30 1992-01-15 Pharmaceutical compositions containing orally absorbable glycosamimoglycans
EP92100732A EP0497162B1 (en) 1991-01-30 1992-01-17 Pharmaceutical compositions containing orally absorbable glycosaminoglycans
DE69212608T DE69212608T2 (de) 1991-01-30 1992-01-17 Arzneimittel enthaltend oral absorbierbare Glycosaminoglycane
ES92100732T ES2090368T3 (es) 1991-01-30 1992-01-17 Composiciones farmaceuticas que contienen glucosaminoglicanos absorbibles por via oral.
CA002059865A CA2059865C (en) 1991-01-30 1992-01-22 Pharmaceutical compositions containing orally absorbable glycosaminoglycans
JP4013943A JPH0755907B2 (ja) 1991-01-30 1992-01-29 経口吸収可能なグリコサミノグリカンを含有する製剤
KR1019920001330A KR100210359B1 (ko) 1991-01-30 1992-01-30 경구용 글리코스아미노글리칸을 함유하는 의약 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO910024A IT1245761B (it) 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.

Publications (3)

Publication Number Publication Date
ITBO910024A0 true ITBO910024A0 (it) 1991-01-30
ITBO910024A1 ITBO910024A1 (it) 1992-07-30
IT1245761B IT1245761B (it) 1994-10-14

Family

ID=11337212

Family Applications (1)

Application Number Title Priority Date Filing Date
ITBO910024A IT1245761B (it) 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.

Country Status (8)

Country Link
US (1) US5252339A (it)
EP (1) EP0497162B1 (it)
JP (1) JPH0755907B2 (it)
KR (1) KR100210359B1 (it)
CA (1) CA2059865C (it)
DE (1) DE69212608T2 (it)
ES (1) ES2090368T3 (it)
IT (1) IT1245761B (it)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1256236B (it) * 1992-12-23 1995-11-29 Mediolanum Farmaceutici Srl Oligosaccaridi aventi attivita' biologica e procedimento per la loro preparazione di glicosaminoglicani
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
CA2150552C (en) * 1993-09-30 1999-12-21 Akikazu Takada Antithrombotic
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
US6262255B1 (en) 1995-04-05 2001-07-17 Biomm, Inc. Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them
GB2305604B (en) * 1995-09-29 1999-06-23 Quest Vitamins Ltd Carrier base material
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US6476005B1 (en) 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US6645948B2 (en) 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) * 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
IL127826A0 (en) * 1998-12-29 1999-10-28 Laster Gail Restenosis drug therapy
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
CA2361268C (en) 1999-02-01 2014-06-10 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
JP4911865B2 (ja) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物
EP1390048A2 (en) * 2001-02-16 2004-02-25 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
DK1372611T3 (da) * 2001-03-26 2006-09-18 Novartis Ag Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
JP4084199B2 (ja) * 2001-05-09 2008-04-30 メディプレックス コーポレーション 両親媒性ヘパリン誘導体の粘膜吸収を増加させるための製造方法
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
EP1406640A2 (en) * 2001-06-12 2004-04-14 Keryx Biopharmceuticals Inc. Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060229276A1 (en) * 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006298791A (ja) * 2005-04-18 2006-11-02 Kotobuki Seiyaku Kk グリコサミノグリカン又はその塩を含む経口投与用医薬品、健康食品又は栄養薬品組成物。
US8298602B2 (en) * 2005-10-11 2012-10-30 Purecircle Sdn Bhd Process for manufacturing a sweetener and use thereof
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
EP2526950A1 (en) 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
KR20110007614A (ko) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2525783A1 (en) * 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
EP2834635A4 (en) * 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
HRP20220158T1 (hr) 2012-05-21 2022-04-15 Insmed Incorporated Sustavi za liječenje plućnih infekcija
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
CA2949078C (en) 2014-05-15 2022-09-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3548052A (en) * 1964-10-27 1970-12-15 Canada Packers Ltd Heparin compositions and methods of using same
US3482014A (en) * 1966-06-29 1969-12-02 Canada Packers Ltd Orally active heparin and method for making and using same
US3506642A (en) * 1967-07-03 1970-04-14 Canada Packers Ltd Stable orally active heparinoid complexes
US3574832A (en) * 1968-05-29 1971-04-13 American Cyanamid Co Therapeutic heparin-surfactant compositions
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
IT1062779B (it) * 1974-04-04 1985-01-14 Crinos Industria Farmaco Composizione farmaceutica contenente un fattore eparinoidico
IT1069492B (it) * 1976-10-13 1985-03-25 Alfa Farmaceutici Spa Composizione farmaceutica sommini stratrice per via orale contenente un fattore eparinoide sospeso in un veicolo oleoso costituito da triace tato di glicerina
GB1591306A (en) * 1976-10-23 1981-06-17 Choay Sa Liposomes containing heparin and a process for obtaining them
FR2492259A1 (fr) * 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
US4510135A (en) * 1982-04-21 1985-04-09 Research Corporation Orally administered heparin
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
CH656533A5 (de) * 1982-12-10 1986-07-15 Sandoz Ag Therapeutisches praeparat enthaltend hydrierte ergotalkaloide und niedermolekulares heparin.
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
EP0189427B1 (en) * 1984-05-21 1989-02-08 BODOR, Nicholas S. Orally active heparin multiplets
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents

Also Published As

Publication number Publication date
EP0497162A1 (en) 1992-08-05
JPH0543471A (ja) 1993-02-23
CA2059865C (en) 1999-01-26
KR100210359B1 (ko) 1999-07-15
US5252339A (en) 1993-10-12
JPH0755907B2 (ja) 1995-06-14
KR920014467A (ko) 1992-08-25
CA2059865A1 (en) 1992-07-31
DE69212608D1 (de) 1996-09-12
EP0497162B1 (en) 1996-08-07
IT1245761B (it) 1994-10-14
ES2090368T3 (es) 1996-10-16
DE69212608T2 (de) 1996-11-28
ITBO910024A1 (it) 1992-07-30

Similar Documents

Publication Publication Date Title
ITBO910024A0 (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale
DK0585252T3 (da) Farmaceutiske formuleringer
ATA129892A (de) Pharmazeutische zusammensetzung
DK0515312T3 (da) Farmaceutisk præparat
FI981777A (fi) Farmaseuttinen ainekoostumus
FI921060A (fi) Farmaceutiska aerosolformuleringar
DE4291156T1 (de) Verbesserte pharmazeutische Zusammensetzungen
ITBO910113A1 (it) Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
NO920067D0 (no) Foradditiv for droevtyggere
FI923581A (fi) Farmaceutisk kombinationsformation
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
DK481989A (da) Farmaceutiske formuleringer
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
MX9200622A (es) Composicion farmaceutica
MX9200146A (es) Composiciones farmaceuticas deglutibles
DE4294862T1 (de) Pharmazeutische Komposition
DK0511991T3 (da) Farmaceutisk formulering
FI941566A (fi) Suun kautta annettava trimetoprim-liuos
ITPD920141A1 (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
SE9103213D0 (sv) Farmaceutisk komposition
SE9101348D0 (sv) Pharmaceutical composition
KR920014777U (ko) 약제 휘산기구
ITMI912766A1 (it) Composizione farmaceutica contenente n-acetil-cisteina
IT8803429A0 (it) Composizioni farmaceutiche contenenti eparina o eparinoidi assorbibili per via orale
BR9206845A (pt) Composto famacêutico

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970115